Probuphine's FDA Panel Return: Efficacy Concerns Despite Narrowed Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Have Braeburn and Titan demonstrated their subdermal buprenorphine implant is non-inferior to buprenorphine sublingual tablets in stable opioid-dependent patients?